How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?

References

• Centers for Disease Control and Prevention (CDC). Shingles (herpes zoster); [accessed 2022 Jun 23]. https://www.cdc.gov/shingles/hcp/clinical-overview.html.
   Google Scholar
• Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109:1–14.
   Google Scholar
• Curran D, Callegaro A, Fahrbach K, Neupane B, Vroling H, van Oorschot D, Yawn BP. Meta-regression of herpes zoster incidence worldwide. Infect Dis Ther. 2022;11:389–403. doi:10.1007/s40121-021-00567-8.
   PubMed Web of Science ®Google Scholar
• Kawai K, Yawn BP. Risk factors for herpes zoster: a systematic review and meta-analysis. Mayo Clin Proc. 2017;92:1806–21. doi:10.1016/j.mayocp.2017.10.009.
   PubMed Web of Science ®Google Scholar
• Suaya JA, Chen SY, Li Q, Burstin SJ, Levin MJ. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1:ofu049. doi:10.1093/ofid/ofu049.
   PubMedGoogle Scholar
• Yanni EA, Ferreira G, Guennec M, El Hahi Y, El Ghachi A, Haguinet F, Espie E, Bianco V. Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the clinical practice research datalink 2000-2012. BMJ Open. 2018;8:e020528. doi:10.1136/bmjopen-2017-020528.
   PubMed Web of Science ®Google Scholar
• Bardach AE, Palermo C, Alconada T, Sandoval M, Balan DJ, Nieto Guevara J, Gomez J, Ciapponi A, Andrei G. Herpes zoster epidemiology in Latin America: a systematic review and meta-analysis. PLoS One. 2021;16(8):e0255877. doi:10.1371/journal.pone.0255877.
   PubMed Web of Science ®Google Scholar
• Kawai K, Rampakakis E, Tsai TF, Cheong HJ, Dhitavat J, Covarrubias AO, Yang L, Cashat-Cruz M, Monsanto H, Johnson K, et al. Predictors of postherpetic neuralgia in patients with herpes zoster: a pooled analysis of prospective cohort studies from North and Latin America and Asia. Int J Infect Dis. 2015;34:126–31. doi:10.1016/j.ijid.2015.03.022.
   PubMed Web of Science ®Google Scholar
• Rampakakis E, Pollock C, Vujacich C, Toniolo Neto J, Ortiz Covarrubias A, Monsanto H, Johnson KD. Economic burden of herpes zoster (“culebrilla”) in Latin America. Int J Infect Dis. 2017;58:22–26. doi:10.1016/j.ijid.2017.02.021.
   PubMed Web of Science ®Google Scholar
• Boutry C, Hastie A, Diez-Domingo J, Tinoco JC, Yu CJ, Andrews C, Beytout J, Caso C, Cheng HS, Cheong HJ, et al. The adjuvanted recombinant zoster vaccine confers long-term protection against herpes zoster: interim results of an extension study of the pivotal phase 3 clinical trials ZOE-50 and ZOE-70. Clin Infect Dis. 2022;74:1459–67. doi:10.1093/cid/ciab629.
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–84. doi:10.1056/NEJMoa051016.
   PubMed Web of Science ®Google Scholar
• Merck & Co, Inc. ZOSTAVAX® (Zoster Vaccine Live); [accessed 2022 Aug 5]. https://www.fda.gov/media/82524/download.
   Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103–08. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Shingrix Recommendations; [accessed 2022 Aug 12]. https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/recommendations.html#:~:text=CDC%20recommends%20Shingrix%20/recombinant%20zoster,prior%20episode%20of%20herpes%20zoster.
   Google Scholar
• Patterson BJ, Buck PO, Curran D, Van Oorschot D, Carrico J, Herring WL, Zhang Y, Stoddard JJ. Estimated public health impact of the recombinant zoster vaccine. Mayo Clin Proc Innov Qual Outcomes. 2021;5:596–604. doi:10.1016/j.mayocpiqo.2021.03.006.
   PubMedGoogle Scholar
• Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States. Vaccine. 2018;36:5037–45. doi:10.1016/j.vaccine.2018.07.005.
   PubMed Web of Science ®Google Scholar
• Carpenter CF, Aljassem A, Stassinopoulos J, Pisacreta G, Hutton D. A cost-effectiveness analysis of an adjuvanted subunit vaccine for the prevention of Herpes Zoster and post-herpetic neuralgia. Open Forum Infect Dis. 2019;6:ofz219. doi:10.1093/ofid/ofz219.
   PubMed Web of Science ®Google Scholar
• McGirr A, Van Oorschot D, Widenmaier R, Stokes M, Ganz ML, Jung H, Varghese L, Curran D. Public health impact and cost-effectiveness of non-live adjuvanted recombinant zoster vaccine in Canadian adults. Appl Health Econ Health Policy. 2019;17:723–32. doi:10.1007/s40258-019-00491-6.
   PubMed Web of Science ®Google Scholar
• Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K. A cost-effectiveness analysis of vaccination for prevention of herpes zoster and related complications: input for national recommendations. Ann Intern Med. 2019;170:380–88. doi:10.7326/M18-2347.
   PubMed Web of Science ®Google Scholar
• van Oorschot DAM, Hunjan M, Bracke B, Lorenc S, Curran D, Starkie-Camejo H. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme. BMJ Open. 2019;9:e025553. doi:10.1136/bmjopen-2018-025553.
   PubMed Web of Science ®Google Scholar
• Van Oorschot D, Anastassopoulou A, Poulsen Nautrup B, Varghese L, von Krempelhuber A, Neine M, Lorenc S, Curran D. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Hum Vaccin Immunother. 2019;15:34–44. doi:10.1080/21645515.2018.1509645.
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, von Krempelhuber A, Anastassopoulou A. Assessment of the potential public health impact of herpes zoster vaccination in Germany. Hum Vaccin Immunother. 2017;13:2213–21. doi:10.1080/21645515.2017.1345399.
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Matthews S, Hain J, Salem AE, Schwarz M. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany. Hum Vaccin Immunother. 2021;17:5296–303. doi:10.1080/21645515.2021.2002085.
   PubMed Web of Science ®Google Scholar
• Volpi A, Boccalini S, Dari S, Clarke C, Curran D, Loiacono I, Pitrelli A, Puggina A, Tosatto R, Van Oorschot D, et al. The potential public health impact of herpes zoster vaccination in the 65 years of age cohort in Italy. Hum Vaccin Immunother. 2020;16:327–34. doi:10.1080/21645515.2019.1657753.
   PubMed Web of Science ®Google Scholar
• de Boer PT, van Lier A, de Melker H, van Wijck AJM, Wilschut JC, van Hoek AJ, Postma MJ. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines. BMC Med. 2018;16:228. doi:10.1186/s12916-018-1213-5.
   PubMed Web of Science ®Google Scholar
• Lee C, Jiang N, Tang H, Ye C, Yuan Y, Curran D. Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing. Hum Vaccin Immunother. 2021;17:3735–46. doi:10.1080/21645515.2021.1932216.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Mizukami A, Holl K, Curran D, Van Oorschot D, Varghese L, Shiragami M. The potential public health impact of herpes zoster vaccination of people aged ≥ 50 years in Japan: results of a Markov model analysis. Dermatol Ther (Heidelb). 2018;8:269–84. doi:10.1007/s13555-018-0236-3.
   PubMed Web of Science ®Google Scholar
• Teng L, Mizukami A, Ng C, Giannelos N, Curran D, Sato T, Lee C, Matsuki T. Cost-effectiveness analysis update of the adjuvanted recombinant zoster vaccine in Japanese older adults. Dermatol Ther (Heidelb). 2022;12:1447–67. doi:10.1007/s13555-022-00744-8.
   PubMed Web of Science ®Google Scholar
• Shiragami M, Mizukami A, Kaise T, Curran D, Van Oorschot D, Bracke B, Watanabe D. Cost-effectiveness of the adjuvant recombinant zoster vaccine in Japanese adults aged 65 years and older. Dermatol Ther (Heidelb). 2019;9:281–97. doi:10.1007/s13555-019-0291-4.
   PubMed Web of Science ®Google Scholar
• Udayachalerm S, Renouard MG, Anothaisintawee T, Thakkinstian A, Veettil SK, Chaiyakunapruk N. Incremental net monetary benefit of herpes zoster vaccination: a systematic review and meta-analysis of cost-effectiveness evidence. J Med Econ. 2022;25:26–37. doi:10.1080/13696998.2021.2008195.
   PubMed Web of Science ®Google Scholar
• Meredith NR, Armstrong EP. Cost-effectiveness of herpes zoster vaccines in the U.S.: a systematic review. Prev Med Rep. 2022;29:101923. doi:10.1016/j.pmedr.2022.101923.
   PubMedGoogle Scholar
• Sociedade Brasileira de Imunizações (SBIm). Nota Técnica SBIm: vacina herpes-zóster inativada recombinante (Shingrix®; [accessed 2022 Aug 12]. https://sbim.org.br/informes-e-notas-tecnicas/sbim/1692-nota-tecnica-sbim-vacina-herpes-zoster-inativada-recombinante-shingrix-220608.
   Google Scholar
• Instituto Nacional de Estadìstica y Censos (INDEC). Estimaciones y proyecciones de población 2010-2040. Total del paìs; [accessed 2022 Jun 23]. https://www.indec.gob.ar/ftp/cuadros/publicaciones/proyeccionesyestimaciones_nac_2010_2040.pdf.
   Google Scholar
• Instituto Brasileiro de Geografia e Estatística (IBGE). Projeções da População (Projeções da população por sexo e idades); [accessed 2022 Jun 23]. https://www.ibge.gov.br/estatisticas/sociais/populacao/9109-projecao-da-populacao.html?=&t=resultados.
   Google Scholar
• Consejo Nacional de Población (CONAPO). Proyecciones de la Población de México y de las Entidades Federativas, 2016-2050. Proyecciones de la Población de los Municipios de México, 2015-2030 (base 1); [accessed 2021 Nov 30]. https://datos.gob.mx/busca/dataset/proyecciones-de-la-poblacion-de-mexico-y-de-las-entidades-federativas-2016-2050.
   Google Scholar
• Instituto Nacional de Estadística (INE). Chile. Proyecciones de población. CUADROS ESTADÍSTICOS. Proyección base 2017. Estimaciones y proyecciones 2002-2035, comuna y área urbana y rural; [accessed 2021 Nov 30]. https://www.ine.cl/estadisticas/sociales/demografia-y-vitales/proyecciones-de-poblacion.
   Google Scholar
• DANE. Proyecciones de población. Serie nacional de población por área, sexo y edad para el periodo 2018 – 2070 [accessed 2021 Nov 30]. https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion.
   Google Scholar
• Instituto Nacional de Estadìstica y Censos (INDEC). TABLA DE MORTALIDAD 2008-2010. TOTAL DEL PAÍS. AMBOS SEXOS; [accessed 2022 Aug 7]. https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.indec.gob.ar%2Fftp%2Fcuadros%2Fpoblacion%2Ftm_0810_totalpais.xls&wdOrigin=BROWSELINK.
   Google Scholar
• Instituto Brasileiro de Geografia e Estatística (IBGE). Tábuas Completas de Mortalidade (Ambos os Sexos) [accessed 2021 Nov 30]. https://www.ibge.gov.br/estatisticas/sociais/populacao/9126-tabuas-completas-de-mortalidade.html?=&t=resultados.
   Google Scholar
• Consejo Nacional de Población (CONAPO). Proyecciones de la Población de México y de las Entidades Federativas, 2016-2050. Dufunciones 1950 - 2050; [accessed 2021 Nov 30]. https://datos.gob.mx/busca/dataset/proyecciones-de-la-poblacion-de-mexico-y-de-las-entidades-federativas-2016-2050/.
   Google Scholar
• Departamento de Estadísticas e Información de Salud (DEIS). Estadísticas de Mortalidad. Defunciones según grupo de edad, región, gran grupo de causas de muerte y sexo. Chile; 2014 [accessed 2021 Nov 30]. https://deis.minsal.cl/#estadisticas.
   Google Scholar
• DANE. Defunciones no fetales 2019. Cuadro 1. Defunciones, por área donde ocurrió la defunción y sexo, según grupos de edad. Total nacional; [accessed 2021 Nov 30]. https://www.dane.gov.co/index.php/estadisticas-por-tema/salud/nacimientos-y-defunciones/defunciones-no-fetales/defunciones-no-fetales-2019.
   Google Scholar
• Antoniolli L, Rodrigues C, Borges R, Goldani LZ. Epidemiology and clinical characteristics of herpes zoster in a tertiary care hospital in Brazil. Braz J Infect Dis. 2019;23:143–45. doi:10.1016/j.bjid.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Wollan PC, Kurland MJ, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc. 2011;86:88–93. doi:10.4065/mcp.2010.0618.
   PubMed Web of Science ®Google Scholar
• Abreu AJL, Venys A, Jacob W, Silva T, Henrique A, Gopala K, Barros ENC. Burden of herpes zoster among Brazilian adults – a hospital-based study. Geriatr Gerontol Aging. 2021;15:e0210035. doi:10.53886/gga.e0210035.
   Google Scholar
• Bollea-Garlatti ML, Bollea-Garlatti LA, Vacas AS, Torre AC, Kowalczuk AM, Galimberti RL, Ferreyro BL. Clinical characteristics and outcomes in a population with disseminated herpes zoster: a retrospective cohort study. Actas Dermosifiliogr. 2017;108:145–52. doi:10.1016/j.ad.2016.10.009.
   PubMedGoogle Scholar
• Rozenek M, Romani A, Aronson S, Ramilo MD, Abellan V, Perez MA, Camera L. Herpes zoster in elderly adults in a community hospital in Buenos Aires. June 2013-May 2014. Medicina (B Aires). 2017;77:24–30.
   PubMed Web of Science ®Google Scholar
• de Martino Mota A, Carvalho-Costa FA. Varicella zoster virus related deaths and hospitalizations before the introduction of universal vaccination with the tetraviral vaccine. J Pediatr (Rio J). 2016;92:361–66. doi:10.1016/j.jped.2015.10.003.
   PubMed Web of Science ®Google Scholar
• DGIS. Egresos Hospitalarios, Urgencias y Defunciones. Cubos dinámicos. Secretaría de Salud DGIS Mexico; [accessed 2020 Aug 16]. http://www.dgis.salud.gob.mx/contenidos/basesdedatos/bdc_egresoshosp_gobmx.html.
   Google Scholar
• Toniolo-Neto J, Psaradellis E, Karellis A, Rampakakis E, Rockett TY, Sampalis JS, Johnson KD, Monsanto HA, Acosta CJ. Measuring herpes zoster disease burden in Sao Paulo, Brazil: a clinico-epidemiological single-center study. Clinics (Sao Paulo). 2018;73:e243. doi:10.6061/clinics/2018/e243.
   PubMed Web of Science ®Google Scholar
• Vujacich C, de Wouters L, Margari A, Gordóvil M, Kawai K, Lemos E, Rampakakis E, Pollock C, White R, Acosta CJ, et al. Assessment of burden of illness due to herpes zoster in Argentina: a prospective observational study. Value Health. 2013;16:A668. doi:10.1016/j.jval.2013.08.1925.
   Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader K, Levin M, Johnson R, Oxman M, Patrick D, Camden S, Mansi JA. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain. 2010;11:1211–21. doi:10.1016/j.jpain.2010.02.020.
   PubMed Web of Science ®Google Scholar
• You JHS, Ming WK, Tsang OT, Chan PK. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults. PLoS One. 2019;14:e0210005. doi:10.1371/journal.pone.0210005.
   PubMed Web of Science ®Google Scholar
• Nieto Guevara J, Guzman-Holst A. Laboratory-based surveillance in Latin America: attributes and limitations in evaluation of pneumococcal vaccine impact. Hum Vaccin Immunother. 2021;17:4667–72. doi:10.1080/21645515.2021.1972709.
   PubMed Web of Science ®Google Scholar
• Damm O, Ultsch B, Horn J, Mikolajczyk RT, Greiner W, Wichmann O. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;15:533. doi:10.1186/s12889-015-1861-8.
   PubMed Web of Science ®Google Scholar
• Garnett GP, Grenfell BT. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol Infect. 1992;108:513–28. doi:10.1017/s0950268800050019.
   PubMed Web of Science ®Google Scholar
• Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect. 2010;138:469–81. doi:10.1017/S0950268809990768.
   PubMed Web of Science ®Google Scholar
• Guzzetta G, Poletti P, Merler S, Manfredi P. The epidemiology of herpes zoster after varicella immunization under different biological hypotheses: perspectives from mathematical modeling. Am J Epidemiol. 2016;183:765–73. doi:10.1093/aje/kwv240.
   PubMed Web of Science ®Google Scholar
• Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 2002;20:2500–07. doi:10.1016/s0264-410x(02)00180-9.
   PubMed Web of Science ®Google Scholar
• Leung J, Dooling K, Marin M, Anderson TC, Harpaz R. The impact of universal varicella vaccination on herpes zoster incidence in the United States: comparison of birth cohorts preceding and following varicella vaccination program launch. J Infect Dis. 2022;226:S470–77. doi:10.1093/infdis/jiac255.
   PubMed Web of Science ®Google Scholar
• Harder T, Siedler A. Systematic review and meta-analysis of chickenpox vaccination and risk of herpes zoster: a quantitative view on the “exogenous boosting hypothesis”. Clin Infect Dis. 2019;69:1329–38. doi:10.1093/cid/ciy1099.
   PubMed Web of Science ®Google Scholar
• Harpaz R. Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. Expert Rev Vaccines. 2019;18:793–811. doi:10.1080/14760584.2019.1646129.
   PubMed Web of Science ®Google Scholar
• Talbird SE, La EM, Mauskopf J, Altland A, Daniels V, Wolfson LJ. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccines. 2018;17:1021–35. doi:10.1080/14760584.2018.1538801.
   PubMed Web of Science ®Google Scholar
• Brazil Ministry of Health, SUS Informatics Department (DATASUS). Tabnet. National immunization program information system. Immunizations since 1994. Coverages (“Coberturas”); [accessed 2022 Nov 30]. http://tabnet.datasus.gov.br/cgi/webtabx.exe?bd_pni/cpnibr.def.
   Google Scholar
• de Salud Argentina M. Coberturas de Vacunación por Jurisdicción. Calendario Nacional de Vacunación 2009-2020; [accessed 2022 Dec 5]. https://bancos.salud.gob.ar/sites/default/files/2021-12/coberturas-de-vacunacion-por-jurisdiccion-cnv-2009-2020.pdf.
   Google Scholar
• de Salud M. Informe de Cobertura Nacional de Inmunizaciones año; 2022 [accessed 2022 Dec 5]. https://vacunas.minsal.cl/wp-content/uploads/2022/08/Informe-de-Coberturas_2022_enero_junio.pdf.
   Google Scholar
• Pawaskar M, Gil-Rojas Y, Irene Parellada C, Rey-Velasco A, Beltran C, Prieto E, Lasalvia P. The impact of universal varicella vaccination on the clinical burden of varicella in Colombia: a national database analysis, 2008-2019. Vaccine. 2022;40:5095–102. doi:10.1016/j.vaccine.2022.07.012.
   PubMed Web of Science ®Google Scholar
• Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24:494–500. doi:10.1016/j.coi.2012.06.002.
   PubMed Web of Science ®Google Scholar
• Laemmle L, Goldstein RS, Kinchington PR. Modeling varicella zoster virus persistence and reactivation - closer to resolving a perplexing persistent state. Front Microbiol. 2019;10:1634. doi:10.3389/fmicb.2019.01634.
   PubMed Web of Science ®Google Scholar
• Syed YY. Recombinant zoster vaccine (Shingrix®): a review in herpes zoster. Drugs Aging. 2018;35:1031–40. doi:10.1007/s40266-018-0603-x.
   PubMed Web of Science ®Google Scholar